Based on our previous work, we aimed to use AI combined with STMs and other clinical factors to predict EGFR mutations, common and uncommon EGFR mutations, and ALK rearrangement status in NSCLC patients. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.